Annexon (NASDAQ:ANNX - Get Free Report) was upgraded by equities researchers at Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Monday,Zacks.com reports.
Other research analysts have also issued reports about the company. HC Wainwright reaffirmed a "buy" rating and set a $14.00 target price on shares of Annexon in a research report on Friday, August 15th. Needham & Company LLC decreased their target price on shares of Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $12.50.
Check Out Our Latest Research Report on ANNX
Annexon Trading Up 6.5%
Shares of ANNX traded up $0.14 during trading hours on Monday, hitting $2.31. The company had a trading volume of 1,955,819 shares, compared to its average volume of 1,094,346. The company has a market capitalization of $253.85 million, a PE ratio of -1.79 and a beta of 1.30. Annexon has a one year low of $1.28 and a one year high of $7.85. The company's fifty day moving average price is $2.47 and its two-hundred day moving average price is $2.31.
Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.02. Analysts forecast that Annexon will post -0.96 earnings per share for the current year.
Hedge Funds Weigh In On Annexon
Hedge funds and other institutional investors have recently made changes to their positions in the company. Matauro LLC acquired a new stake in shares of Annexon in the second quarter valued at approximately $27,000. BNP Paribas Financial Markets acquired a new stake in shares of Annexon in the fourth quarter valued at approximately $59,000. 49 Wealth Management LLC acquired a new stake in shares of Annexon in the second quarter valued at approximately $29,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Annexon in the second quarter valued at approximately $29,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Annexon in the second quarter valued at approximately $32,000.
About Annexon
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Read More
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access